Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer

US9816996B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9816996-B2
Application numberUS-201214234783-A
CountryUS
Kind codeB2
Filing dateJul 26, 2012
Priority dateJul 26, 2011
Publication dateNov 14, 2017
Grant dateNov 14, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-β1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for diagnosis of epithelial ovarian cancer comprising quantitatively detecting a β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment and a β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment present in a body fluid derived from a test subject, and determining that the test subject is diagnosed to be likely to have epithelial ovarian cancer when the detection results of the β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment and the β1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment are greater than a predetermined cut-off value, wherein the β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment is detected using at least one antibody or antibody fragment selected from the group consisting of an antibody for detecting an epithelial ovarian cancer marker that recognizes as an epitope a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1; and a fragment of the antibody for detecting an epithelial ovarian cancer marker that recognizes as an epitope a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, and wherein the predetermined cut-off value is 95 percentile of the detection results of the β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment and the β1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment in body fluid derived from normal individuals or patients other than epithelial ovarian cancer, and wherein the antibody is produced by a hybridoma identified by International Accession No. FERM BP-11494 or FERM BP-11495. 2. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment is detected using at least one antibody or antibody fragment selected from the group consisting of an anti-β-1,6-N-acetylglucosaminyltransferase 5B antibody recognizing as an epitope a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, and a fragment of the anti-β-1,6-N-acetylglucosaminyltransferase 5B antibody, wherein the fragment specifically recognizes β-1,6-N-acetylglucosaminyltransferase 5B. 3. The method for diagnosis of epithelial ovarian cancer of claim 2 , wherein the anti-β-1,6-N-acetylglucosaminyltransferase 5B antibody is produced by a hybridoma identified by International Accession No. FERM BP-11496, FERM BP-11497, FERM BP-11498, or FERM BP-11499. 4. A monoclonal antibody produced by a hybridoma identified by International Accession No. FERM ABP-11494 or FERM ABP-11495. 5. A hybridoma identified by International Accession No. FERM ABP-11494. 6. A hybridoma identified by International Accession No. FERM ABP-11495.

Assignees

Inventors

Classifications

  • of the ovaries · CPC title

  • against enzymes · CPC title

  • Reproductive system, e.g. ovaria, uterus, testes, prostate · CPC title

  • one of the fusion partners being a B or a T lymphocyte · CPC title

  • Physics · mapped topic

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9816996B2 cover?
The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-β1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,3…
Who is the assignee on this patent?
Sogabe Maki, Kubota Tomomi, Togayachi Akira, and 6 more
What technology area does this patent fall under?
Primary CPC classification G01N33/57545. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).